This has sparked significant interest among researchers in targeting key enzymes and signaling pathways involved in the inflammatory response—such as COX-2, NF-κB, IL-6, and IL-1β—as potential therapeutic strategies for prostate cancer. Here, IL1B is linked to prostate cancer.